fizzy-related protein Inhibitors
Chemical inhibitors of fizzy-related protein can modulate its activity through various biochemical pathways. SB-431542 acts upon the TGF-beta signaling pathway by specifically targeting the ALK5 receptor, which is crucial for the phosphorylation of SMAD proteins. These proteins are downstream effectors that, when activated, can promote fizzy-related protein activity. Thus, inhibition by SB-431542 leads to a decrease in SMAD protein activation and a consequent reduction in the activity of fizzy-related protein. Similarly, LDN-193189 operates by impeding BMP signaling, another pathway that influences fizzy-related protein through the phosphorylation of SMAD proteins. The inhibition of this signal transduction pathway by LDN-193189 can result in decreased activation of fizzy-related protein. Y-27632 is a selective inhibitor of ROCK kinases, which play a significant role in cell shape, motility, and contraction-processes that are essential for the proper function of fizzy-related protein. The action of Y-27632 can thus alter the dynamics of the cytoskeleton and cell adhesion, impacting fizzy-related protein's role in the cell cycle.
Continuing with the theme of pathway inhibition, U0126 and PD98059 both target MEK enzymes within the MAPK/ERK pathway, which is an important regulator of cellular proliferation and thus, fizzy-related protein activity. By preventing the activation of ERK, these compounds can reduce the overall activity of fizzy-related protein. LY294002 inhibits PI3K, leading to a reduction in Akt activity-a kinase that can regulate proteins involved in cell survival, including fizzy-related protein. SP600125 inhibits JNK, which can affect fizzy-related protein function, particularly in apoptosis and stress responses. Rapamycin suppresses the mTOR pathway, which is associated with cell proliferation, and its inhibition can affect the synthesis and function of proteins like fizzy-related protein. Palbociclib, by inhibiting CDK4/6, can arrest the cell cycle at the G1 phase, which in turn inhibits the action of fizzy-related protein in cell cycle progression. Nutlin-3, by stabilizing and activating p53, can suppress the cell cycle progression functions of fizzy-related protein. Lastly, vorinostat, as an HDAC inhibitor, alters gene expression which may lead to downregulation of fizzy-related protein activity. Each of these inhibitors, through their unique mechanisms, can regulate the activity of fizzy-related protein by modulating different signaling pathways and molecular targets within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
This small molecule inhibitor targets the TGF-beta signaling pathway, which is known to be involved in the regulation of fizzy-related protein activities, such as cell cycle control and apoptosis. SB-431542 specifically inhibits TGF-beta type I receptor (ALK5), which can lead to decreased phosphorylation and activation of SMAD proteins, downstream effectors that could otherwise promote fizzy-related protein activity. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a potent inhibitor of BMP signaling. As fizzy-related protein is known to be regulated by BMP signals through SMAD protein phosphorylation, inhibiting this pathway with LDN-193189 would reduce the activity of fizzy-related protein by preventing its BMP-mediated activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK kinases, which are implicated in various cellular functions including cell shape, motility, and contraction. By inhibiting ROCK, Y-27632 can alter the cytoskeletal dynamics and cell adhesion processes that are necessary for proper fizzy-related protein function, particularly in its role in cell cycle progression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
This compound is an inhibitor of MEK, a kinase involved in the MAPK/ERK pathway. Fizzy-related protein is influenced by the MAPK/ERK pathway, which modulates various cellular processes including proliferation. Inhibition by U0126 would prevent the activation of ERK, thereby reducing the activity of fizzy-related protein that depends on this signaling for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Since fizzy-related protein activity can be influenced by PI3K/Akt pathway, inhibition of PI3K by LY294002 would lead to a decrease in Akt activity. This reduction in Akt activity would result in diminished fizzy-related protein activity as Akt can regulate a plethora of proteins involved in cell survival and cycle progression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. JNK activity can regulate fizzy-related protein function, particularly in stress responses and apoptosis. By inhibiting JNK, SP600125 would prevent the phosphorylation and activation of transcription factors that may regulate fizzy-related protein activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, similar to U0126, and it works to block the MAPK/ERK pathway. Since the MAPK/ERK pathway has a role in regulating fizzy-related protein, inhibition by PD98059 would lead to decreased ERK activation and subsequent reduction in fizzy-related protein activity related to cell cycle progression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, rapamycin can suppress the mTOR pathway, which is involved in cell growth and proliferation. Fizzy-related protein, being associated with the cell cycle, could be indirectly inhibited by rapamycin through its action on mTOR, leading to reduced protein synthesis and cell proliferation where fizzy-related protein plays a role. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor, directly affecting cell cycle progression at the G1 phase. Since fizzy-related protein is involved in cell cycle control, inhibition of CDK4/6 by palbociclib would lead to G1 arrest, subsequently inhibiting the role of fizzy-related protein in cell cycle progression. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
This molecule inhibits the interaction between p53 and MDM2, leading to stabilization and activation of p53. Since fizzy-related protein can be involved in p53-regulated processes such as cell cycle arrest and apoptosis, nutlin-3 would enhance p53 activity, which can suppress the cell cycle progression functions of fizzy-related protein. | ||||||